Pivoting to HER2-positive disease, the team reviews emerging intracranial-response data showing T-DXd outperforming TKIs despite the blood–brain barrier. Once a TKI purist, Dr. Yan concedes that T-DXd’s potency inside the skull reshapes second-line doctrine and blurs the historic systemic/CNS; radiation vs. medical oncologist divide, especially after data from ASCO.
Brain Mets: T-DXd Beats BBB
Recommended Videos
